Medtronic and Qualcomm, Inc. announced a partnership to develop continuous glucose monitoring systems for patients with type 2 diabetes.
The companies initially plan on developing a single-use continuous glucose monitoring system for general practitioners. The agreement will combine Medtronic’s experience in diabetes management with Qualcomm’s experience in wireless technologies.
Medtronic currently has a MiniMed 530G system that includes an insulin pump and a glucose sensor. The system helps lower patients’ hemoglobin A1c levels and their risk of nerve, eye, and kidney problems. The FDA approved the MiniMed 530G system in September 2013.